SCHEDULE: Cormorant Asset Management Reports 7.72% Praxis Stake

Cormorant Asset Management, LP and Bihua Chen disclose a 7.72% beneficial ownership in Praxis Precision Medicines, Inc. common stock.

Summary

• Cormorant Asset Management, LP and Bihua Chen collectively hold 1,625,000 shares of Praxis Precision Medicines, Inc. Common Stock.
• This ownership represents 7.72% of the total outstanding shares of the company.
• The percentage is calculated based on 21,045,781 shares outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q.
• Both Cormorant Asset Management, LP and Bihua Chen have shared voting and shared dispositive power over all 1,625,000 shares.
• The shares are held by various Cormorant Funds, with Cormorant Global Healthcare Master Fund, LP specifically noted as having the right to receive dividends or proceeds from more than 5% of the shares.

Sentiment

Score: 5

Explanation: The filing is a factual report of beneficial ownership, indicating a significant, continued stake by an institutional investor. It does not contain performance data or forward-looking statements that would typically influence sentiment.

Positives

• A significant institutional investor, Cormorant Asset Management, LP, maintains a substantial 7.72% beneficial ownership stake in Praxis Precision Medicines, Inc., indicating continued investment interest.

Risks

• The filing itself does not detail specific operational or financial risks of the issuer.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional ownership, potentially signaling confidence from a major investor.

Key Dates

Keywords

Praxis Precision Medicines, Cormorant Asset Management, Bihua Chen, SEC filing, Schedule 13G, beneficial ownership, common stock, investment adviser, institutional investor, healthcare, biotechnology